About 500,000 cases of chikungunya—including over 400 deaths—were recorded worldwide in 2023.5
VIMKUNYA:
The first and only
virus-like particle
vaccine for chikungunya1,2
The FIRST virus-like particle
(VLP) vaccine indicated to
help prevent chikungunya1,2
Mostly mild to moderate adverse reactions
In clinical studies, the most common adverse reactions in people 12–64 years old were injection site pain (23.7%), fatigue (19.9%), headache (18.0%), and myalgia (17.6%). In people 65 and older, the most common adverse reactions were injection site pain (5.4%), myalgia (6.3%), and fatigue (6.3%)1
Almost everyone had
a
seroresponse by
3 weeks
98% of people ages 12–64
and 87% of those 65+1,*
APPROVED for ages 12 and over1
*Among adults and adolescents aged 12–64, 97.8% achieved a seroresponse at Day 22 with VIMKUNYA, vs 1.2% with placebo. Among
people aged ≥65, 87.3% achieved a seroresponse at Day 22 with VIMKUNYA, vs 1.1% with placebo.1
BEHIND THE TECH
See what makes
VLPs different
VLPs different
Regions that have reported chikungunya cases according to the World Health Organization, 20206
Preventing a debilitating
viral disease7
Chikungunya virus (CHIKV) is one of the most common viral diseases spread by mosquitoes8 and can lead to painful symptoms in over 75% of people who become infected.9,10 So it's important to take steps to take on chikungunya.
Learn moreabout the risks
-
3 OUT OF 4
people infected with CHIKV get symptoms,† like severe joint pain, fever, and headache.9
-
2 OUT OF 5
can have chronic symptoms, like joint pain, that last for months or years.9,11,‡
†In a systematic literature review, meta-analysis of 8 studies determined that the overall symptomatic rate of chikungunya infection was 75% (n=912/1217; 95% CI, 0.63-0.84).9
‡Including a meta-analysis of 34 studies across 15 countries showing that more than 40% of patients developed severe long-term symptoms, lasting for months.11
View Transcript
Video Transcript
You see every type of traveller.
A team of travellers united under one thing – your protection against chikungunya, a mosquito-borne disease.
And with VIMKUNYA, you can help protect a range of people from becoming infected with chikungunya.
VIMKUNYA is a vaccine indicated for prevention of disease caused by chikungunya virus in individuals 12 years of age and older.
VIMKUNYA is approved under accelerated approval based on anti-chikungunya virus neutralizing antibody levels.
Confirmatory trials are required.
Do not administer VIMKUNYA to individuals with a history of a severe allergic reaction (anaphylaxis) to any of its components.
Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions.
Immunocompromised individuals, including individuals receiving immunosuppressive therapy may have a diminished immune response to VIMKUNYA.
Syncope (fainting) may occur.
Procedures should be in place to avoid injury.
The most common solicited adverse reactions in individuals aged 12 to 64 (greater than 10%) were injection site pain, fatigue, headache, and myalgia.
And in individuals 65 and older (greater than 5%) were injection site pain, myalgia and fatigue.
VIMKUNYA is a virus-like particle (VLP) vaccine, which means it’s designed to mimic the chikungunya virus without causing disease.
VIMKUNYA induced a robust seroresponse within 3 weeks after vaccination.
So, are your patients ready to face chikungunya?
VIMKUNYA, let’s go.
Please see full Prescribing Information via the link on-screen.
Watch the
latest video
See how you can help your patients protect themselves from chikungunya when they travel.1
